Their findings give an epigenetic basis for immunotherapy success in BCP-ALL patients, as the TRAIL/death receptor system plays an important role in the anti-leukemic actions of anti-CD19 CAR-T cells. Here, CD19 is linked to acute lymphoblastic leukemia.